Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development LLC) in combination with bortezomib, lenalidomide and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT).
Efficacy was evaluated in PERSEUS (ClinicalTrials.gov. Identifier: NCT03710603),